

Tim Cardilin^{1,2}, Astrid Zimmermann³, Mats Jirstrand², Joachim Almquist^{1,2}, Samer El Bawab³, and Johan Gabrielsson⁴

¹Chalmers University of Technology, Gothenburg, Sweden, ²Fraunhofer-Chalmers Centre, Gothenburg, Sweden, ³Merck, Darmstadt, Germany, ⁴Swedish University of Agricultural Sciences, Uppsala, Sweden

Introduction

A Tumor Growth Inhibition (TGI) model is used to study the impact of ionizing radiation and exposure to a probe compound. The proposed model contains the determinants of synergy between the two provocations. The Tumor Static Concentration (TSC) curve is then generated as a function of radiation dose and probe compound concentration². The curvature of the TSC function demonstrates a significant synergistic effect.

Methods

Xenograft data from a combination therapy experiment where mice were treated with ionizing radiation (IR) and/or a probe compound. Ten mice made up each of the four treatment arms: Vehicle, radiation, compound, and radiation + compound.

The model (Fig. 1) is an extension of the standard TGI model where cells go through damage states before final cell death. IR acts as an instant mass transfer between the healthy state and first damage state. The compound stimulates both the natural- and the IR-induced death processes.




Fig. 1

The corresponding system of differential equations reads

$$\begin{aligned} \frac{dV_1}{dt} &= k_g V_1 - k_k S_1(C) V_1 - k_{IR} R(D) S_2(C) V_1 \\ \frac{dV_2}{dt} &= k_k S_1(C) V_1 + k_{IR} R(D) S_2(C) V_1 - k_k V_2 \\ \frac{dV_3}{dt} &= k_k V_2 - k_k V_3 \end{aligned}$$

with

$$S_1(C) = 1 + a C, \quad S_2(C) = 1 + b C$$

A nonlinear mixed-effects approach based on the FOCE algorithm was used to model the population¹.

Exposure profiles




Fig. 2

Results

Sample of fit for each treatment arm

- Compound (green) has little effect when given as single-agent. Radiation (red) has a moderate effect
- Combined (purple) the effect is synergistic




Fig. 3

Estimated parameter values

Parameter	Estimate	BSV (%)
k_g (day ⁻¹)	0.17	2.8
k_k (day ⁻¹)	0.032	-
V_0 (mm ³)	88	16
k_{IR} (Gy ⁻¹ · day ⁻¹)	0.12	-
a (mL · µg ⁻¹)	0.56	-
b (mL · µg ⁻¹)	0.12	64
s (%)	25	-

- Parameter estimates within biologically reasonable ranges
- Model successfully captured an interaction between radiation and drug exposure
- Interaction (synergy) parameter b varies greatly across individuals

TSC curve for radiation + drug




Fig. 4

- TSC curve (blue) shows significant curvature
- Green area represents tumor shrinkage
- Red area represents tumor growth

Extended Tumor Static Concentration curve

Condition for the tumor to be in stasis – the average growth rate of the main compartment is zero

$$\frac{1}{T} \int_0^T k_g - k_k S_1(C) - k_{IR} R(D) S_2(C) dt = 0$$

A daily administration schedule gives for the average drug concentration \bar{C} and average radiation dose \bar{D}

$$(k_g - k_k) - k_k a \bar{C} - k_{IR} \bar{D} - k_{IR} b \bar{C} \bar{D} = 0$$

This equation describes a curve in the $\bar{C}\bar{D}$ -plane which identifies the necessary concentration-radiation dose pairs for tumor stasis. The larger the curvature, the greater the synergy is between the compounds (Fig 4).

Conclusions

- Radiation-modified TGI model successfully captures the data and interaction effect
- Significant synergy between the two treatments – visualized by the curvature of the TSC curve
- The TSC concept helps in defining optimal concentration and dose ranges for the two drugs to achieve tumor shrinkage

References

- Almquist J, Leander J, Jirstrand M. Using sensitivity equations for computing gradients of the FOCE and FOCEI approximations to the population likelihood. *J Pharmacokinetic Pharmacodyn* (2015) 42: 191-209.
- Cardilin T, Sostelly A, Gabrielsson J, El Bawab S, Amendt C, Jirstrand M. Modelling and Analysis of Tumor Growth Inhibition for Combination Therapy using Tumor Static Concentration Curves. *PAGE 24* (2015) Abstr 3568 [www.page-meeting.org/?abstract=3568].
- Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E, Germani M, Poggessi I, Rocchetti M. Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents. *Cancer Res.*, (2004) 64:1094-1101.